

International Expert Forum: B Cell Targeting in Glomerular Disease: A New Era in Treatment



ISN International Expert Forum: B Cell Targeting in Glomerular Disease: A New Era in Treatment

Forum Location: NH Collection Sevilla (Avenida Diego Martinex Barrio, N8, 41013 Sevilla, Spain)

Thursday, 29 January 2026

Time

18.00 – 21.00	Welcome and Dinner
---------------	--------------------

Friday, 30 January 2026

Time	Talk Topic	Speaker		
9.00 – 9.10	Welcome on behalf of ISN	Jonathan Barratt &		
R CELL DEVELO	DMENT FUNCTION AND POLE IN HEALTH	Richard Lafayette		
B CELL DEVELOPMENT, FUNCTION AND ROLE IN HEALTH Session Moderators: Heather Reich and Katherine Bull				
9.10 – 9.50	B cell development (30 mins + Q & A)	Bill Robinson		
9.50 – 10.30	Function of the mucosal immune system (30 mins + Q & A)	Oliver Pabst		
10.30 - 11.00	Coffee Break			
11.00 – 11.30	Role of BAFF and APRIL (20 mins + Q & A)	Edward Carr		
11.30 – 12.00	B cell immunity in children (20 mins + Q & A)	Hélène Decaluwe		
MEASURING B CELL ACTIVITY: CURRENT PRACTICE & UNMET NEED Session Moderators: Suceena Alexander and Adrian Liew				
12.00 – 12.30	Current immunological testing for B cell activity (20 mins + Q & A)	Renato Monteiro		
12.30 – 13.00	Exploratory methods to measure depth of B cell and plasma cell depletion in clinical trials (20 mins + Q & A)	Daniel Suan		
13.00 – 14.00	Lunch			
LESSON LEARNT FROM TARGETING B CELLS IN HAEMATOONCOLOGY & RHEUMATOLOGY Session Moderators: Sydney Tang and Richard Lafayette				
14.00 – 14.30	Treatment of B cell lymphomas, multiple myeloma and AL amyloidosis (20 mins + Q & A)	David Miklos		
14.30 – 15.00	Treatment of autoimmune rheumatology diseases (20 mins + Q & A)	Chi-Chiu Mok		
15.00 – 15.30	Coffee Break			
MOVING INTO THE KIDNEYS				
Session Moderators: Katherine Bull and Jonathan Barratt				
15.30 – 16.00	The unmet need for better B cell control in glomerular disease (20 mins + Q & A)	David Jayne		
16.00 – 16.30	A role for kidney resident B/plasma cells in kidney disease progression? (20 mins + Q & A)	Heather Reich		
16.30 – 17.00	B cell modulation in children-a sensible approach? (20 mins + Q & A)	Hui Kim Yap		
17.00 – 17.10	Close for the day			



International Expert Forum: B Cell Targeting in Glomerular Disease: A New Era in Treatment



Saturday, 31 January 2026

Time	Talk Topic	Speaker		
09.00 – 09.10	Welcome for the day	Jonathan Barratt & Richard Lafayette		
B CELL THERAPIES IN GLOMERULAR DISEASE Session Moderators: Tingting Li and Jonathan Barratt				
9.10 – 9.30	A rationale for inhibiting BAFF and/or APRIL	Dana Rizk		
9.30 – 9.50	A rationale for depleting B/plasma cells with monoclonal and bispecific antibodies	Richard Lafayette		
9.50 – 10.10	A rationale for depleting B/plasma cells with cell therapies	Brad Rovin		
10.10 - 10.40	Panel discussion- Which is the right approach?			
10.40 – 11.10	Coffee Break			
B CELL TARGETING IN GLOMERULAR DISEASES-STATE OF THE ART AND UNMET NEED IN 2026 (PART 1) Session Moderators: Goh Su Mein & Richard Lafayette				
11.10 – 11.40	IgA nephropathy (20 mins + Q & A)	Suceena Alexander		
11.40 – 12.10	Lupus nephritis (20 mins + Q & A)	Juan Manuel Mejía Vilet		
12.10 - 12:40	Membranous nephropathy (20 mins + Q & A)	Vivek Jha		
12.40 – 13.40	Lunch			
B CELL TARGETING IN GLOMERULAR DISEASES-STATE OF THE ART AND UNMET NEED IN 2026 (PART 2) Session Moderators: Liz Lightstone and Adrian Liew				
13.40 – 14.10	ANCA associated vasculitis (20 mins + Q & A)	Rachel Jones		
14.10 – 14.40	Minimal change and Focal Segmental Glomerulosclerosis (20 mins + Q & A)	Adrian Liew		
14.40 – 15.10	C3 Glomerulopathy and Immune Complex Mediated MPGN (20 mins + Q & A)	Carla Nester		
15.10 – 15.40	Coffee			
THE FUTURE OF B CELL THERAPIES IN THE TREATMENT OF GLOMERULAR DISEASES				
15.40 – 16.10	tors: Suceena Alexander and Heather Reich	Marina Vivarelli		
	In children (20 mins + Q & A)			
16.10 – 16.40	In adults (20 mins + Q & A)	Jonathan Barratt		
16.40 – 17.00	Close	Jonathan Barratt & Richard Lafayette		

The following companies have provided funding towards this independent forum and have had no editorial input or control over the program, content development or choice of expert speakers:

Vera Therapeutics, Otsuka, Alexion, Biogen, Roche and Climb Bio.